Bioventus stockholders elect all 12 director nominees and ratify Grant Thornton as auditor at 2026 annual meeting

The following proposals were voted upon at the 2026 Annual Meeting and the final voting results with respect to each such proposal are set forth below. At the 2026 Annual Meeting, the stockholders elected the following directors to serve on the Company’s Board of Directors until the 2027 annual meeting of stockholders and until each such director’s respective successor is elected and qualified, or until each such director’s death, resignation or removal, based on the following votes: Nominee For Withheld Broker Non-Votes William A. Hawkins 67,405,961 1,128,994 6,744,219 John A. Bartholdson 68,365,980 168,975 6,744,219 Patrick J. Beyer 68,062,114 472,841 6,744,219 Robert E. Claypoole 68,360,467 174,488 6,744,219 Philip G. Cowdy 67,748,512 786,443 6,744,219 Ajay Dhankhar 68,459,149 75,806 6,744,219 Mary Kay Ladone 67,160,936 1,374,019 6,744,219 Michelle McMurry-Heath 68,073,685 461,270 6,744,219 Guido J. Neels 68,049,659 485,296 6,744,219 Guy P. Nohra 67,767,651 767,304 6,744,219 Susan M

The stockholders also ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 75,228,481 Shares for, 5,021 Shares against, 45,672 Shares abstaining, and no broker non-votes.